問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Taipei Veterans General Hospital

Recruiting

List

1000Cases

2017-12-19 - 2025-07-15

Phase III

A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL COMPARING THE EFFICACY AND SAFETY OF POLATUZUMAB VEDOTIN IN COMBINATION WITH RITUXIMAB AND CHP (R-CHP) VERSUS RITUXIMAB AND CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA

  • Condition/Disease

    DIFFUSE LARGE B-CELL LYMPHOMA

  • Test Drug

    Polatuzumab vedotin

Participate Sites
6Sites

Recruiting5Sites

高志平
Taipei Veterans General Hospital

2016-08-01 - 2021-01-10

Phase III

A Phase 3, Double-Blind, Placebo-controlled Study of Quizartinib (AC220) Administered in Combination with Induction and Consolidation Chemotherapy, and Administered as Maintenance Therapy in Subjects 18 to 75 Years Old with Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (QuANTUM-First)

  • Condition/Disease

    Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia

  • Test Drug

    Quizartinib (AC220)

Participate Sites
6Sites

Recruiting3Sites

Terminated3Sites

柯博伸
Taipei Veterans General Hospital

2019-05-01 - 2026-12-31

Phase I/II

A Phase 1/2 Dose Escalation and Dose Expansion Study of BA3011 in Patients with Advanced Solid Tumors

  • Condition/Disease

    Advanced Solid Tumors

  • Test Drug

    BA3011

Participate Sites
4Sites

Recruiting4Sites

2020-02-01 - 2022-02-27

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2019-10-01 - 2023-01-13

Phase II

A phase 2, multicenter open-label, non-randomized study of bavituximab plus pembrolizumab in patients with advanced gastric or gastroesophageal cancer who have progressed on or after at least one prior standard therapy

  • Condition/Disease

    Gastric Cancer / GastroEsophageal Cancer

  • Test Drug

    Bavituximab

Participate Sites
4Sites

Recruiting4Sites

2022-01-01 - 2025-02-28

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2021-05-01 - 2024-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting1Sites

Recruiting4Sites

2021-06-01 - 2026-02-01

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2021-02-26 - 2025-12-10

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2020-12-01 - 2024-10-01

Phase I

A Phase 1/2, Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of D-1553 in Subjects With Advanced or Metastatic Solid Tumors With KRasG12C Mutation

  • Condition/Disease

    Advanced or Metastatic Solid Tumors With KRasG12C Mutation

  • Test Drug

    D-1553

Participate Sites
4Sites

Recruiting4Sites

1 76 77 78 79 80 100
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB